Inflation Pressures Broaden Beyond Energy as Consumer Prices Reaccelerate in Key Sectors AIGenerated Fake Evidence Sparks Legal Action Implications for Digital Forensics and Entertainment Industry AI Economy Reshapes Job Market BlueCollar Skilled Trades Gain as College EntryLevel Roles Slow Estate Transparency Concerns Family Disputes Over Control of Mothers Affairs Spain Blocks Polymarket and Kalshi Over Gambling License Requirements SonoTek Corporation Concludes Fiscal Q4 2026 Earnings Call Key Updates Awaited AGNCN Q1 2026 Earnings EPS Beat Shows Resilient Earnings Power Preferred Dividend Coverage Solid Rio Tinto Q4 2025 Earnings EPS Falls Short of Expectations Despite Positive Stock Movement MAT Q1 2026 Earnings NarrowerthanExpected Loss Drives Modest Stock Uptick CNS Q1 2026 Earnings Earnings Miss Estimates as EPS Falls Short RMR Q1 2026 Earnings EPS Misses Estimates Amid Flat Revenue Disclosure CBC Q1 2026 Earnings EPS Surpasses Estimates Amid Modest Share Decline BioNexus Gene Lab Corp BGLC Surges 844 Testing Key Resistance at 230 Limbach Holdings LMB Narrows Near Support as Trading Volume Remains Subdued Woodside Energy Group WDS Edges Higher as Support Holds Steady Franklin BSP Realty Trust FBRT Holds Near Support Amid Modest Decline Welltower Holds Nearly Flat Consolidating Near 216 Amid Sector Caution Microsofts AI Cost Dilemma When Automation Bills Exceed Human Payroll Solaris Resources Inc SLSR Q1 2026 Earnings Net Loss Narrows as Exploration Ramps Stock Slips iHuman Inc IH Edges Higher as Stock Tests Key Resistance Near 172 Tyra Biosciences TYRA Q1 2026 Earnings Net Loss Slightly Wider Than Street Estimates RDWR Q1 2026 Earnings EPS Misses Estimates by 1231 as Stock Rises 138 Tetra Tech Inc Q1 2026 Earnings EPS Beat Driven by Strong Execution Amidst Uncertain Revenue Trajectory MMSI Q1 2026 Earnings Strong EPS Beat Drives Positive Market Response Intellia Therapeutics NTLA Q1 2026 Earnings NarrowerThanExpected Loss Fuels Market Optimism ENDRA Life Sciences Q1 2026 Earnings WiderThanExpected Loss as PreRevenue Biotech Continues Development Calidi Biotherapeutics Q4 2025 Earnings Narrowed Loss Surprises Stock Declines